MRE11 and breast carcinoma: In a panel of breast cancer lines (MCF7, MDA-MB-231, MDA-MB-436, SKBR-3, MDA-MB-175VII), we also evaluated Mre11 at baseline and after cisplatin treatment (Supplementary Fig. 3D and E).